Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study
2024; Multidisciplinary Digital Publishing Institute; Volume: 13; Issue: 14 Linguagem: Inglês
10.3390/jcm13143992
ISSN2077-0383
AutoresSilviu-Horia Morariu, Ovidiu Simion Cotoi, Oana Mirela Tiucă, Adrian Băican, Laura Gheucă Solovăstru, H. Decean, Ilarie Brihan, Katalin Silaghi, Viorica Biro, Diana Șerban-Pescar, Ioana Măgureanu, Mircea Ambros, Roxana Ioana Ilcuș, L. Prodan, Andreea Beatrix Bălan, Mădălina Aurelia Husariu, Dumitrița Lenuța Guguluș, Radu Alexandru Stan, Vlad Mihai Voiculescu, Alin Codruț Nicolescu,
Tópico(s)Inflammatory mediators and NSAID effects
Resumo: Psoriasis is an immune-mediated chronic disorder associated with various comorbidities. Even though biologics and small-molecule inhibitors are the mainstay treatment for moderate-to-severe psoriasis, there is no current consensus regarding which agent should be used for a specific type of patient. This paper aims to test the reliability of blood-count-derived inflammatory markers in assessing treatment response to biologics and small-molecule inhibitors in psoriasis.
Referência(s)